Takeda Pharmaceutical, Eisai, and Nippon Chemiphar offeredearly retirement programs over the past year, a Jiho survey revealed. It appears that not all of them are looking at downsizing, however, with some aggressively seeking to “rejuvenate” their employees by replacing ones…
HOME > ORGANIZATION
ORGANIZATION
- EFPIA Issues Proposals for Japanese CEA System, Says “Cannot Accept” Expansion without Corrective Steps
April 21, 2021
- Regulations for DX, Pre-Symptomatic Disease Up for JPMA Committee Discussion
April 20, 2021
- Asia Trade Groups Discuss Regional Differences in Nonclinical Evaluations of Human Cell Products
April 20, 2021
- JGA Bitterly Reprimands Kobayashi Kako for Application Document Fabrication
April 20, 2021
- Asian Pharma Groups Agree to Ensure Smooth Drug Reviews amid COVID-19 Crisis
April 16, 2021
- Plaintiffs of HPV Vaccine Suits Urge LDP Group to Hear Stories of Sufferers
April 16, 2021
- Scandals Making It Difficult to Recommend Generics to Members: Kyokai Kenpo Chair
April 16, 2021
- Govt Should Set API-by-API Targets for Biosimilars: Society Chief
April 15, 2021
- Hold Off on Nichi-Iko Products for Now to Remove Generic Distrust: Pharmacy Chief
April 9, 2021
- Wakayama Council Makes List of 500 Drugs Commonly Used in Region, Snubs Nichi-Iko/Kobayashi Kako Generics
April 9, 2021
- Industry Group Rolls Out Barcode Reader App for E-Labeling
April 8, 2021
- Generic Industry Group Requests Blanket Manufacturing Checkups for 39 Member Firms
March 31, 2021
- 27.2% Pharmacists Want Total Product Switch from Nichi-Iko to Other Makers, 56.6% Hoping Partial Switch: Survey
March 31, 2021
- Generic Use Rate at 79.4% in October-December 2020: JGA
March 29, 2021
- Industry Group Poised for Pilot Rollout of E-Labeling App in April, Looks to Sales Reps for Popularization
March 26, 2021
- JPMA Renews Call for Post-Launch Innovation Review in 2021 Proposal
March 24, 2021
- Japan Govt Should Change Course on Consistent Price Cuts for On-Patent Drugs: FPMAJ Exec
March 22, 2021
- FPMAJ Adopts FY2021 Project Plans with Focus on Pricing Reform
March 19, 2021
- Trade Groups Push Proper Pricing of Innovative Drugs to Restore Attractiveness of Japan: LDP Confab
March 19, 2021
- With Aducanumab in Mind, Outgoing Chuikyo Payer Rep Floats Rule to Reward Cost Cuts for Pricey Meds
March 18, 2021
ページ
The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
The past month has seen two significant milestones in healthcare price control measures in Japan: The first “off-year” NHI reimbursement price cuts, and release of the first results under Japan’s “cost-effectiveness assessment” system. Both milestones have been anticipated for quite…